BioCentury
ARTICLE | Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

November 6, 2019 11:30 PM UTC

As it continues to rely on biosimilars as a growth driver, Biogen has expanded its deal with Samsung Bioepis to include two new ocular biosimilars in certain major markets, as well as rights in China to anti-TNF therapies.

Biogen Inc. (NASDAQ:BIIB) will pay $100 million up front to Samsung Bioepis, the JV it shares with Samsung BioLogics Co. Ltd. (KOSDAQ:207940). The JV is eligible for $210 million in milestones, plus shared revenues from sales. Biogen may also opt to pay Samsung Bioepis $60 million in order to extend by five years its existing deal for European rights to the JV's anti-TNF portfolio...